Acadian Asset Management’s AVEO Pharmaceuticals, Inc. AVEO Stock Holding History

Acadian Asset Management’s Portfolio AVEO Stock Details AVEO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-42,980	Closed	-$352K	–	1975
2022 Q3	$352K	Buy	+42,980	New	+$330K	﹤0.01%	1083
2021 Q3	–	Sell	-14,289	Closed	-$94K	–	2154
2021 Q2	$94K	Buy	+14,289	New	+$98.5K	﹤0.01%	1643
2020 Q4	–	Sell	-21,763	Closed	-$129K	–	2438
2020 Q3	$129K	Buy	+21,763	New	+$108K	﹤0.01%	1591
2016 Q4	–	Sell	-1,911	Closed	-$17K	–	1831
2016 Q3	$17K	Buy	+1,911	New	+$18K	﹤0.01%	1168

Other funds holding AVEO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NAM

Nexpoint Asset Management Dallas, Texas $1.49B AUM 61.08% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

WIC

Water Island Capital New York $896M AUM 107.59% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

Acadian Asset Management's AVEO Position: Q4 2022 in Review

Acadian Asset Management sold out of AVEO Pharmaceuticals, Inc. (AVEO) in Q4 2022, closing a stake of 42,980 shares — an estimated $352K sold.

Acadian Asset Management first reported a position in AVEO in Q3 2016 and held it in 4 quarters. The position peaked at $352K in Q3 2022. 110 funds tracked by Wall St. Rank hold AVEO as of Q4 2022.

Acadian Asset Management reported no remaining AVEO Pharmaceuticals, Inc. position as of Q4 2022 after selling out during the quarter.
Acadian Asset Management sold 42,980 AVEO Pharmaceuticals, Inc. shares in Q4 2022, an estimated $352K.
Acadian Asset Management first reported a position in AVEO Pharmaceuticals, Inc. in Q3 2016 and held it in 4 quarters.
Acadian Asset Management's AVEO Pharmaceuticals, Inc. position peaked at $352K in Q3 2022.
110 funds tracked by Wall St. Rank held AVEO Pharmaceuticals, Inc. as of Q4 2022.

Based on Acadian Asset Management's 13F filing for Q4 2022, filed 14 Feb 2023.